NCT04744831 · FLOW

Participant flow

Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer · Source last updated 2026-01-14

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

description
Participants were randomized to receive intravenous T-DXd administered at a dose of 5.4 mg/kg every 3 weeks (Q3W).
id
FG000
title
T-DXd 5.4 mg/kg Q3W
description
Participants were randomized to receive intravenous T-DXd administered at a dose of 6.4 mg/kg every 3 weeks (Q3W).
id
FG001
title
T-DXd 6.4 mg/kg Q3W

periods

drop Withdraws
reasons
group Id
FG000
num Subjects
6
group Id
FG001
num Subjects
4
type
Adverse Event
reasons
group Id
FG000
num Subjects
5
group Id
FG001
num Subjects
5
type
Clinical Progression
reasons
group Id
FG000
num Subjects
2
group Id
FG001
num Subjects
1
type
Death
reasons
group Id
FG000
num Subjects
5
group Id
FG001
num Subjects
1
type
Other
reasons
group Id
FG000
num Subjects
63
group Id
FG001
num Subjects
29
type
Progressive Disease
reasons
group Id
FG000
num Subjects
1
group Id
FG001
num Subjects
0
type
Withdrawal by Subject
milestones
achievements
group Id
FG000
num Subjects
82
group Id
FG001
num Subjects
40
type
STARTED
achievements
group Id
FG000
num Subjects
0
group Id
FG001
num Subjects
0
type
COMPLETED
achievements
group Id
FG000
num Subjects
82
group Id
FG001
num Subjects
40
type
NOT COMPLETED
title
Overall Study

pre Assignment Details

Following adequate study explanation by the investigator or their designee, subjects voluntarily offered signed, informed consent prior to participation in any study procedures.

recruitment Details

A total of 122 participants who met all inclusion criteria and no exclusion criteria were randomized/registered to T-DXd treatment in the United States, Asia-Pacific, and Europe.

Complete source fields